Mads Hald Andersen 

Professor, Centre for Cancer Immune Therapy, Herlev and Gentofte Hospital

Email: mads.hald.andersen@regionh.dk

Mads Hald Andersen, MD, PhD, DSc, is the Director, Professor, and Co-founder of the National Center for Cancer Immune Therapy (CCIT-dk) at Copenhagen University Hospital, Herlev. He holds doctoral degrees from both Copenhagen University and the Technical University of Denmark. His research focuses on cancer immunotherapy, and he has pioneered Immune Modulatory Vaccines (IMVs) targeting the tumor microenvironment (TME). He identified anti-regulatory T cells (anti-Tregs) that selectively target immune-suppressive factors within the TME. With 235+ publications and 20+ patents, he has significantly advanced the field, leading ongoing clinical trials in Europe and the U.S. As a visionary leader in translational research, he combines academic excellence with entrepreneurial innovation, founding biotech companies such as Survac and the Nasdaq-listed IO Biotech.

Herlev and Gentofte Hospital

Herlev and Gentofte Hospital is a leading research institution where specialised research is deeply integrated with clinical practice across all departments. The hospital is internationally recognised for advanced research in cardiopulmonary diseases, focusing on heart failure, arrhythmias, and pulmonary conditions, as well as in oncology, with innovative studies in cancer diagnostics, immunotherapy, and personalized treatment strategies. Dermatology and allergology research are also prominent, addressing chronic skin conditions, autoimmune diseases, and allergy mechanisms. The hospital’s strong academic environment is supported by extensive collaborations with national and international universities, local authorities, and pharmaceutical companies, fostering continuous innovation and improvements in patient care.

Se publikationer her